Alcon Inc. (ACL) Tops Q2 EPS View By 14c; Guides FY08 Higher Than Expectations
More News related to ACL
- Alcon Discontinues Development of Anecortave Acetate for Intraocular Pressure Reduction
- Alcon Announces Second Quarter 2009 Financial Release and Conference Call Dates
- Anthony Clark - Financial Results Highlights for Year Ended March 31, 2009
- wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
- Anthony Clark - Report on the New Strategic Initiatives
Alcon Inc. (NYSE: ACL) reports Q2 EPS of $1.88, 14 cents better than the analyst estimate of $1.74. Revenues for the quarter were $1.74 billion, versus the consensus of $1.68 billion.
Sees FY08 EPS $6.48 to $6.54 versus consensus of $6.44.
Alcon, Inc. engages in the development, manufacture, and marketing of pharmaceuticals, surgical equipment and devices, and consumer eye care products to treat eye diseases and disorders.
Sign up at EasyStockAlerts.com To Be Alerted To Your Stock News Today!
Related Categories
EarningsGuidance
Hot List
Stocks Mentioned
-89.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
